Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase

Current Opinion in Chemical Biology

Volumn 23, Issue , 2014, Pages 47-55

  Hailfinger, Stephan ^a   Lenz, Georg ^b   Thome, Margot ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 [4 (2 DIETHYLAMINOETHYLAMINO) 3 NITROPHENYL] 1,4 DIPHENYL 1,2,4 TRIAZOLIUM 3 THIOLATE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOLECULAR SCAFFOLD; MUCOSA ASSOCIATED LYMPHOID TISSUE PROTEIN 1; MUCOSA ASSOCIATED LYMPHOID TISSUE PROTEIN 1 INHIBITOR; PECAZINE; PROTEINASE; PROTEINASE INHIBITOR; THIORIDAZINE; UNCLASSIFIED DRUG; CASPASE; ENZYME INHIBITOR; MALT1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CELL TRANSFORMATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME REGULATION; ENZYME STRUCTURE; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; LYMPHOMA, B-CELL;

ANIMALS; CASPASES; ENZYME INHIBITORS; HUMANS; LYMPHOMA, B-CELL; NEOPLASM PROTEINS;

EID: 84921898265     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2014.09.025     Document Type: Review

References (60)

1. Nogai H., Dorken B., Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011, 29:1803-1811.
2. Dalla-Favera R. Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges. J Clin Invest 2012, 122:3396-3397.
3. Isaacson P.G., Du M.Q. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004, 4:644-653.
4. Uren A.G., O'Rourke K., Aravind L.A., Pisabarro M.T., Seshagiri S., Koonin E.V., Dixit V.M. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000, 6:961-967.
5. Lucas P.C., Yonezumi M., Inohara N., McAllister-Lucas L.M., Abazeed M.E., Chen F.F., Yamaoka S., Seto M., Nunez G. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 2001, 276:19012-19019.
6. Zhou H., Du M.Q., Dixit V.M. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005, 7:425-431.
7. Gaide O., Favier B., Legler D.F., Bonnet D., Brissoni B., Valitutti S., Bron C., Tschopp J., Thome M. CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation. Nat Immunol 2002, 3:836-843.
8. Che T., You Y., Wang D., Tanner M.J., Dixit V.M., Lin X. MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation. J Biol Chem 2004, 279:15870-15876.
9. Shinohara H., Maeda S., Watarai H., Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007, 204:3285-3293.
10. Sun L., Deng L., Ea C.K., Xia Z.P., Chen Z.J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004, 14:289-301.
11. Noels H., van Loo G., Hagens S., Broeckx V., Beyaert R., Marynen P., Baens M. A novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2-MALT1 fusions. J Biol Chem 2007, 282:10180-10189.
12. Oeckinghaus A., Wegener E., Welteke V., Ferch U., Arslan S.C., Ruland J., Scheidereit C., Krappmann D. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 2007, 26:4634-4645.
13. Rebeaud F., Hailfinger S., Posevitz-Fejfar A., Tapernoux M., Moser R., Rueda D., Gaide O., Guzzardi M., Iancu E.M., Rufer N., et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 2008, 9:272-281.
14. Coornaert B., Baens M., Heyninck K., Bekaert T., Haegman M., Staal J., Sun L., Chen Z.J., Marynen P., Beyaert R. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008, 9:263-271.
15. Hailfinger S., Nogai H., Pelzer C., Jaworski M., Cabalzar K., Charton J.E., Guzzardi M., Decaillet C., Grau M., Dorken B., et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A 2011, 108:14596-14601.
16. Staal J., Driege Y., Bekaert T., Demeyer A., Muyllaert D., Van Damme P., Gevaert K., Beyaert R. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011, 30:1742-1752.
17. Uehata T., Iwasaki H., Vandenbon A., Matsushita K., Hernandez-Cuellar E., Kuniyoshi K., Satoh T., Mino T., Suzuki Y., Standley D.M., et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell 2013, 153:1036-1049.
18. Nakaya M., Xiao Y., Zhou X., Chang J.H., Chang M., Cheng X., Blonska M., Lin X., Sun S.C. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 2014, 40:692-705.
19. Jaworski M., Marsland B.J., Gehrig J., Held W., Favre S., Luther S.A., Perroud M., Golshayan D., Gaide O., Thome M. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J 2014, (in press).
20. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
21. Yang Y., Schmitz R., Mitala J., Whiting A., Xiao W., Ceribelli M., Wright G.W., Zhao H., Yang Y., Xu W., et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov 2014, 4:480-493.
22. Dubois S.M., Alexia C., Wu Y., Leclair H.M., Leveau C., Schol E., Fest T., Tarte K., Chen Z.J., Gavard J., et al. A catalytic-independent role for the LUBAC in NF-kappaB activation upon antigen receptor engagement and in lymphoma cells. Blood 2014, 123:2199-2203.
23. Duwel M., Welteke V., Oeckinghaus A., Baens M., Kloo B., Ferch U., Darnay B.G., Ruland J., Marynen P., Krappmann D. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 2009, 182:7718-7728.
24. Marienfeld R., May M.J., Berberich I., Serfling E., Ghosh S., Neumann M. RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem 2003, 278:19852-19860.
25. Baens M., Bonsignore L., Somers R., Vanderheydt C., Weeks S., Nilsson E., Roth R.G., Thome M., Marynen P. MALT1 autoproteolysis is essential for NF-kB-dependent gene transcription in activated lymphocytes. PLOS ONE 2014, 9:e103774.
26. Thome M., Charton J.E., Pelzer C., Hailfinger S. Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2010, 2:a003004.
27. Hailfinger S., Lenz G., Ngo V., Posvitz-Fejfar A., Rebeaud F., Guzzardi M., Penas E.M., Dierlamm J., Chan W.C., Staudt L.M., et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2009, 106:19946-19951.
28. Ferch U., Kloo B., Gewies A., Pfander V., Duwel M., Peschel C., Krappmann D., Ruland J. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009, 206:2313-2320.
29. Rosebeck S., Madden L., Jin X., Gu S., Apel I.J., Appert A., Hamoudi R.A., Noels H., Sagaert X., Van Loo P., et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011, 331:468-472.
30. Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chun Chan F., Meissner B., Bhang H.E., Ruddy D., Kauffmann A., et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014, 20:87-92.
31. Young R.M., Staudt L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013, 12:229-243.
32. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
33. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
34. Rawlings D.J., Sommer K., Moreno-Garcia M.E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006, 6:799-812.
35. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
36. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J.M., Hossfeld D.K., De Wolf-Peeters C., Hagemeijer A., Van den Berghe H., Marynen P. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93:3601-3609.
37. Akagi T., Motegi M., Tamura A., Suzuki R., Hosokawa Y., Suzuki H., Ota H., Nakamura S., Morishima Y., Taniwaki M., et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999, 18:5785-5794.
38. Morgan J.A., Yin Y., Borowsky A.D., Kuo F., Nourmand N., Koontz J.I., Reynolds C., Soreng L., Griffin C.A., Graeme-Cook F., et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999, 59:6205-6213.
39. Pelzer C., Cabalzar K., Wolf A., Gonzalez M., Lenz G., Thome M. MALT1 protease activity is controlled by monoubiquitination. Nat Immunol 2013, 14:337-345.
40. Baens M., Maes B., Steyls A., Geboes K., Marynen P., De Wolf-Peeters C. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000, 156:1433-1439.
41. Ye H., Liu H., Raderer M., Chott A., Ruskone-Fourmestraux A., Wotherspoon A., Dyer M.J., Chuang S.S., Dogan A., Isaacson P.G., et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003, 101:2547-2550.
42. Streubel B., Lamprecht A., Dierlamm J., Cerroni L., Stolte M., Ott G., Raderer M., Chott A. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003, 101:2335-2339.
43. Murga Penas E.M., Hinz K., Roser K., Copie-Bergman C., Wlodarska I., Marynen P., Hagemeijer A., Gaulard P., Loning T., Hossfeld D.K., et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia 2003, 17:2225-2229.
44. Ye H., Gong L., Liu H., Hamoudi R.A., Shirali S., Ho L., Chott A., Streubel B., Siebert R., Gesk S., et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 2005, 205:293-301.
45. Willis T.G., Jadayel D.M., Du M.Q., Peng H., Perry A.R., Abdul-Rauf M., Price H., Karran L., Majekodunmi O., Wlodarska I., et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999, 96:35-45.
46. Zhang Q., Siebert R., Yan M., Hinzmann B., Cui X., Xue L., Rakestraw K.M., Naeve C.W., Beckmann G., Weisenburger D.D., et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999, 22:63-68.
47. Hailfinger S., Pelzer C., Thome M. Detection and measurement of paracaspase MALT1 activity. Methods Mol Biol 2014, 1133:177-188.
48. Hachmann J., Snipas S.J., van Raam B.J., Cancino E.M., Houlihan E.J., Poreba M., Kasperkiewicz P., Drag M., Salvesen G.S. Mechanism and specificity of the human paracaspase MALT1. Biochem J 2012, 443:287-295.
49. Wiesmann C., Leder L., Blank J., Bernardi A., Melkko S., Decock A., D'Arcy A., Villard F., Erbel P., Hughes N., et al. Structural determinants of MALT1 protease activity. J Mol Biol 2012, 419:4-21.
50. Yu J.W., Jeffrey P.D., Ha J.Y., Yang X., Shi Y. Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region. Proc Natl Acad Sci U S A 2011, 108:21004-21009.
51. Qiao Q., Yang C., Zheng C., Fontan L., David L., Yu X., Bracken C., Rosen M., Melnick A., Egelman E.H., et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Mol Cell 2013, 51:766-779.
52. Cabalzar K., Pelzer C., Wolf A., Lenz G., Iwaszkiewicz J., Zoete V., Hailfinger S., Thome M. Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface. PLOS ONE 2013, 8:e72051.
53. Vercammen D., Belenghi B., van de Cotte B., Beunens T., Gavigan J.A., De Rycke R., Brackenier A., Inze D., Harris J.L., Van Breusegem F. Serpin1 of Arabidopsis thaliana is a suicide inhibitor for metacaspase 9. J Mol Biol 2006, 364:625-636.
54. Nagel D., Spranger S., Vincendeau M., Grau M., Raffegerst S., Kloo B., Hlahla D., Neuenschwander M., Peter von Kries J., Hadian K., et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012, 22:825-837.
55. Fontan L., Yang C., Kabaleeswaran V., Volpon L., Osborne M.J., Beltran E., Garcia M., Cerchietti L., Shaknovich R., Yang S.N., et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012, 22:812-824.
56. Sachlos E., Risueno R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., Malig M., McNicol J.D., Fiebig-Comyn A., Graham M., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
57. Schlauderer F., Lammens K., Nagel D., Vincendeau M., Eitelhuber A.C., Verhelst S.H., Kling D., Chrusciel A., Ruland J., Krappmann D., et al. Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase. Angew Chem Int Ed Engl 2013, 52:10384-10387.
58. Mc Guire C., Elton L., Wieghofer P., Staal J., Voet S., Demeyer A., Nagel D., Krappmann D., Prinz M., Beyaert R., et al. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J Neuroinflamm 2014, 11:124.
59. Mc Guire C., Wieghofer P., Elton L., Muylaert D., Prinz M., Beyaert R., van Loo G. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J Immunol 2013, 190:2896-2903.
60. Brustle A., Brenner D., Knobbe C.B., Lang P.A., Virtanen C., Hershenfield B.M., Reardon C., Lacher S.M., Ruland J., Ohashi P.S., et al. The NF-kappaB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest 2012, 122:4698-4709.